| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 274 | 2026 | 2326 | 28.910 |
Why?
|
| Heart-Assist Devices | 64 | 2024 | 568 | 12.040 |
Why?
|
| Stroke Volume | 55 | 2025 | 654 | 5.570 |
Why?
|
| Atrial Fibrillation | 39 | 2024 | 558 | 4.600 |
Why?
|
| Decision Making | 26 | 2024 | 977 | 4.040 |
Why?
|
| Patient Readmission | 28 | 2024 | 769 | 3.900 |
Why?
|
| Heart Transplantation | 19 | 2026 | 680 | 3.270 |
Why?
|
| Decision Support Techniques | 16 | 2022 | 477 | 3.220 |
Why?
|
| Registries | 53 | 2025 | 2406 | 3.150 |
Why?
|
| Quality of Life | 49 | 2025 | 3204 | 3.050 |
Why?
|
| Ventricular Dysfunction, Left | 15 | 2023 | 394 | 3.020 |
Why?
|
| Guideline Adherence | 17 | 2026 | 586 | 2.790 |
Why?
|
| Health Expenditures | 8 | 2025 | 194 | 2.750 |
Why?
|
| Cardiology | 21 | 2025 | 362 | 2.650 |
Why?
|
| Palliative Care | 24 | 2025 | 1020 | 2.620 |
Why?
|
| Humans | 373 | 2026 | 145474 | 2.500 |
Why?
|
| Ventricular Function, Left | 20 | 2024 | 542 | 2.500 |
Why?
|
| Drug Costs | 6 | 2025 | 117 | 2.460 |
Why?
|
| Caregivers | 22 | 2026 | 1073 | 2.320 |
Why?
|
| Patient Participation | 16 | 2025 | 439 | 2.320 |
Why?
|
| Aged | 162 | 2026 | 26153 | 2.210 |
Why?
|
| Hospitalization | 49 | 2025 | 2460 | 2.090 |
Why?
|
| Cardiovascular Agents | 6 | 2025 | 166 | 2.020 |
Why?
|
| United States | 122 | 2026 | 16098 | 2.000 |
Why?
|
| Hospice Care | 9 | 2021 | 227 | 1.990 |
Why?
|
| Ambulatory Care | 11 | 2025 | 609 | 1.940 |
Why?
|
| Defibrillators, Implantable | 15 | 2022 | 382 | 1.900 |
Why?
|
| Patient Discharge | 28 | 2024 | 992 | 1.810 |
Why?
|
| Practice Patterns, Physicians' | 14 | 2026 | 1371 | 1.810 |
Why?
|
| Practice Guidelines as Topic | 18 | 2026 | 1581 | 1.790 |
Why?
|
| Anticoagulants | 18 | 2024 | 748 | 1.720 |
Why?
|
| American Heart Association | 20 | 2025 | 358 | 1.670 |
Why?
|
| Middle Aged | 130 | 2026 | 36215 | 1.660 |
Why?
|
| Male | 187 | 2026 | 72842 | 1.650 |
Why?
|
| Medicare | 32 | 2024 | 903 | 1.640 |
Why?
|
| Terminal Care | 10 | 2025 | 283 | 1.640 |
Why?
|
| Female | 193 | 2026 | 78844 | 1.600 |
Why?
|
| Aged, 80 and over | 72 | 2026 | 8333 | 1.600 |
Why?
|
| Risk Assessment | 34 | 2025 | 3747 | 1.560 |
Why?
|
| Cardiotonic Agents | 10 | 2021 | 94 | 1.560 |
Why?
|
| Stroke | 16 | 2024 | 1270 | 1.440 |
Why?
|
| Outpatients | 10 | 2023 | 447 | 1.440 |
Why?
|
| Treatment Outcome | 61 | 2026 | 11772 | 1.420 |
Why?
|
| Patient Preference | 6 | 2018 | 223 | 1.400 |
Why?
|
| Angiotensin Receptor Antagonists | 14 | 2025 | 115 | 1.380 |
Why?
|
| Health Status | 14 | 2023 | 832 | 1.290 |
Why?
|
| Cardiovascular Diseases | 18 | 2026 | 2187 | 1.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 11 | 2025 | 229 | 1.250 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 1210 | 1.250 |
Why?
|
| Patient-Centered Care | 12 | 2024 | 547 | 1.240 |
Why?
|
| Quality Improvement | 11 | 2026 | 1295 | 1.230 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2025 | 252 | 1.210 |
Why?
|
| Withholding Treatment | 5 | 2019 | 80 | 1.170 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2025 | 1747 | 1.160 |
Why?
|
| Delivery of Health Care | 11 | 2023 | 946 | 1.160 |
Why?
|
| Heart Ventricles | 6 | 2021 | 756 | 1.160 |
Why?
|
| Aminobutyrates | 7 | 2023 | 31 | 1.130 |
Why?
|
| Medication Adherence | 8 | 2026 | 540 | 1.130 |
Why?
|
| Prognosis | 31 | 2024 | 4316 | 1.130 |
Why?
|
| Hemorrhage | 11 | 2024 | 822 | 1.110 |
Why?
|
| Aftercare | 17 | 2023 | 222 | 1.100 |
Why?
|
| Inpatients | 5 | 2023 | 553 | 1.090 |
Why?
|
| Cardiomyopathies | 6 | 2026 | 335 | 1.090 |
Why?
|
| Family | 4 | 2023 | 682 | 1.060 |
Why?
|
| Hospitals | 10 | 2024 | 732 | 1.050 |
Why?
|
| Biphenyl Compounds | 8 | 2023 | 67 | 1.020 |
Why?
|
| Risk Factors | 49 | 2025 | 10885 | 1.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 10 | 2025 | 1419 | 1.010 |
Why?
|
| Valsartan | 6 | 2022 | 32 | 0.980 |
Why?
|
| Cost of Illness | 7 | 2025 | 324 | 0.980 |
Why?
|
| Patient Care Management | 3 | 2017 | 56 | 0.980 |
Why?
|
| Cardiovascular System | 6 | 2024 | 138 | 0.980 |
Why?
|
| Health Care Costs | 8 | 2024 | 425 | 0.960 |
Why?
|
| Consumer Health Information | 3 | 2017 | 49 | 0.930 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 8 | 2025 | 69 | 0.910 |
Why?
|
| Surveys and Questionnaires | 23 | 2024 | 6066 | 0.900 |
Why?
|
| Clinical Decision-Making | 9 | 2024 | 363 | 0.890 |
Why?
|
| Heart Failure, Systolic | 3 | 2018 | 26 | 0.870 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2025 | 232 | 0.860 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 297 | 0.850 |
Why?
|
| Quality Indicators, Health Care | 9 | 2026 | 336 | 0.840 |
Why?
|
| Patient Selection | 10 | 2019 | 738 | 0.830 |
Why?
|
| Patient Reported Outcome Measures | 11 | 2024 | 497 | 0.810 |
Why?
|
| Internet | 4 | 2020 | 689 | 0.810 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 38 | 0.810 |
Why?
|
| Biomedical Research | 3 | 2020 | 717 | 0.810 |
Why?
|
| Symporters | 1 | 2024 | 48 | 0.800 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2020 | 144 | 0.800 |
Why?
|
| Survival Analysis | 14 | 2019 | 1374 | 0.780 |
Why?
|
| Protease Inhibitors | 2 | 2020 | 102 | 0.780 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 777 | 0.770 |
Why?
|
| Cannabis | 3 | 2024 | 509 | 0.770 |
Why?
|
| Follow-Up Studies | 27 | 2024 | 5423 | 0.770 |
Why?
|
| Quality of Health Care | 8 | 2024 | 692 | 0.770 |
Why?
|
| Text Messaging | 5 | 2026 | 182 | 0.750 |
Why?
|
| Heart Injuries | 1 | 2023 | 42 | 0.750 |
Why?
|
| Physicians | 7 | 2023 | 955 | 0.720 |
Why?
|
| Global Health | 2 | 2025 | 403 | 0.720 |
Why?
|
| Spirituality | 1 | 2023 | 87 | 0.710 |
Why?
|
| Diuretics | 4 | 2023 | 68 | 0.700 |
Why?
|
| Telemedicine | 8 | 2026 | 961 | 0.690 |
Why?
|
| Device Removal | 2 | 2020 | 142 | 0.670 |
Why?
|
| Informed Consent | 3 | 2023 | 198 | 0.660 |
Why?
|
| Amyloid Neuropathies, Familial | 3 | 2026 | 26 | 0.650 |
Why?
|
| Transitional Care | 3 | 2021 | 45 | 0.650 |
Why?
|
| Catheter Ablation | 4 | 2020 | 355 | 0.640 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 549 | 0.640 |
Why?
|
| Biomarkers | 8 | 2024 | 4295 | 0.630 |
Why?
|
| Insurance, Health | 3 | 2017 | 310 | 0.630 |
Why?
|
| Patient Care Team | 5 | 2024 | 696 | 0.630 |
Why?
|
| Retrospective Studies | 43 | 2025 | 17291 | 0.620 |
Why?
|
| Health Policy | 3 | 2021 | 400 | 0.620 |
Why?
|
| Adult | 56 | 2026 | 40777 | 0.610 |
Why?
|
| Population Health | 1 | 2020 | 44 | 0.610 |
Why?
|
| Healthcare Disparities | 10 | 2025 | 735 | 0.600 |
Why?
|
| Societies, Medical | 6 | 2024 | 899 | 0.600 |
Why?
|
| Attitude to Death | 4 | 2023 | 76 | 0.600 |
Why?
|
| Propanolamines | 1 | 2019 | 40 | 0.600 |
Why?
|
| Time Factors | 24 | 2026 | 7123 | 0.590 |
Why?
|
| Patient Rights | 1 | 2019 | 11 | 0.590 |
Why?
|
| Length of Stay | 7 | 2018 | 1349 | 0.580 |
Why?
|
| Cause of Death | 8 | 2020 | 470 | 0.580 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2026 | 2588 | 0.580 |
Why?
|
| Drug Substitution | 2 | 2018 | 63 | 0.570 |
Why?
|
| Quality Assurance, Health Care | 3 | 2015 | 342 | 0.560 |
Why?
|
| Medicaid | 4 | 2021 | 467 | 0.560 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 389 | 0.550 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 383 | 0.550 |
Why?
|
| Hospices | 5 | 2021 | 92 | 0.550 |
Why?
|
| Health Status Indicators | 3 | 2020 | 167 | 0.540 |
Why?
|
| Manuscripts, Medical as Topic | 1 | 2017 | 5 | 0.540 |
Why?
|
| Interviews as Topic | 10 | 2025 | 910 | 0.540 |
Why?
|
| Heart Diseases | 2 | 2014 | 341 | 0.530 |
Why?
|
| Attitude to Health | 4 | 2019 | 430 | 0.530 |
Why?
|
| Cocaine | 1 | 2019 | 161 | 0.520 |
Why?
|
| Peer Review | 1 | 2017 | 47 | 0.520 |
Why?
|
| Peer Review, Research | 1 | 2017 | 36 | 0.520 |
Why?
|
| Advance Care Planning | 3 | 2025 | 244 | 0.510 |
Why?
|
| Warfarin | 7 | 2022 | 179 | 0.510 |
Why?
|
| Qualitative Research | 15 | 2026 | 1674 | 0.510 |
Why?
|
| Editorial Policies | 1 | 2017 | 45 | 0.510 |
Why?
|
| Disease Progression | 15 | 2025 | 2864 | 0.500 |
Why?
|
| Disease Management | 7 | 2025 | 653 | 0.500 |
Why?
|
| Insurance Claim Review | 2 | 2014 | 83 | 0.490 |
Why?
|
| Physician-Patient Relations | 3 | 2020 | 588 | 0.490 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 198 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2026 | 881 | 0.490 |
Why?
|
| Angina, Unstable | 3 | 2006 | 83 | 0.480 |
Why?
|
| Stress, Psychological | 3 | 2021 | 1146 | 0.480 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 141 | 0.480 |
Why?
|
| Comorbidity | 14 | 2023 | 1661 | 0.470 |
Why?
|
| Aortic Valve Stenosis | 2 | 2021 | 256 | 0.470 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2025 | 272 | 0.460 |
Why?
|
| Acute Disease | 9 | 2024 | 1036 | 0.460 |
Why?
|
| Colorado | 14 | 2025 | 4553 | 0.450 |
Why?
|
| Digoxin | 1 | 2015 | 27 | 0.450 |
Why?
|
| Cost-Benefit Analysis | 6 | 2026 | 639 | 0.450 |
Why?
|
| Prospective Studies | 20 | 2022 | 8057 | 0.450 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 96 | 0.440 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 1061 | 0.440 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 209 | 0.440 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2022 | 109 | 0.430 |
Why?
|
| Survival Rate | 10 | 2020 | 2090 | 0.430 |
Why?
|
| Multimedia | 1 | 2014 | 13 | 0.430 |
Why?
|
| Heart Rate | 4 | 2020 | 855 | 0.430 |
Why?
|
| Proportional Hazards Models | 14 | 2019 | 1327 | 0.430 |
Why?
|
| Frail Elderly | 2 | 2013 | 136 | 0.420 |
Why?
|
| Neprilysin | 4 | 2024 | 47 | 0.420 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 288 | 0.410 |
Why?
|
| Cohort Studies | 16 | 2023 | 6013 | 0.410 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 444 | 0.410 |
Why?
|
| Hip Prosthesis | 1 | 2014 | 42 | 0.400 |
Why?
|
| Skilled Nursing Facilities | 2 | 2016 | 152 | 0.400 |
Why?
|
| Fluid Therapy | 1 | 2015 | 155 | 0.400 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 65 | 0.400 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 2930 | 0.390 |
Why?
|
| Population Surveillance | 1 | 2017 | 484 | 0.390 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 213 | 0.390 |
Why?
|
| Chest Pain | 2 | 2024 | 99 | 0.390 |
Why?
|
| Socioeconomic Factors | 6 | 2022 | 1323 | 0.390 |
Why?
|
| Health Personnel | 2 | 2022 | 754 | 0.390 |
Why?
|
| Hyperkalemia | 1 | 2013 | 36 | 0.390 |
Why?
|
| Tetrazoles | 6 | 2023 | 50 | 0.380 |
Why?
|
| Preoperative Period | 1 | 2013 | 149 | 0.380 |
Why?
|
| Prosthesis Failure | 1 | 2014 | 125 | 0.380 |
Why?
|
| Hand Strength | 1 | 2014 | 144 | 0.380 |
Why?
|
| Hospital Mortality | 8 | 2023 | 1038 | 0.380 |
Why?
|
| Self Care | 5 | 2025 | 390 | 0.380 |
Why?
|
| Life Expectancy | 2 | 2016 | 73 | 0.370 |
Why?
|
| Electrocardiography | 5 | 2023 | 665 | 0.370 |
Why?
|
| Aortic Valve | 2 | 2021 | 364 | 0.360 |
Why?
|
| Drug Combinations | 7 | 2022 | 396 | 0.360 |
Why?
|
| Models, Statistical | 2 | 2014 | 671 | 0.360 |
Why?
|
| Furosemide | 2 | 2023 | 37 | 0.360 |
Why?
|
| Patient Admission | 3 | 2015 | 220 | 0.360 |
Why?
|
| Cardiac Catheterization | 3 | 2020 | 558 | 0.360 |
Why?
|
| Hemodynamics | 6 | 2023 | 1118 | 0.360 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2022 | 355 | 0.360 |
Why?
|
| Algorithms | 4 | 2022 | 1845 | 0.350 |
Why?
|
| Chronic Disease | 10 | 2022 | 1808 | 0.350 |
Why?
|
| Sex Factors | 9 | 2024 | 2105 | 0.350 |
Why?
|
| Coronary Artery Bypass | 2 | 2011 | 268 | 0.340 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 168 | 0.340 |
Why?
|
| Social Environment | 1 | 2013 | 252 | 0.340 |
Why?
|
| Spouses | 2 | 2025 | 108 | 0.340 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 5904 | 0.340 |
Why?
|
| Eligibility Determination | 3 | 2024 | 72 | 0.330 |
Why?
|
| Myocarditis | 2 | 2022 | 102 | 0.330 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 554 | 0.330 |
Why?
|
| Communication | 6 | 2025 | 975 | 0.320 |
Why?
|
| Health Literacy | 4 | 2022 | 185 | 0.320 |
Why?
|
| Emotions | 7 | 2023 | 574 | 0.320 |
Why?
|
| Income | 3 | 2020 | 202 | 0.320 |
Why?
|
| Research Report | 5 | 2022 | 86 | 0.320 |
Why?
|
| Age Factors | 12 | 2020 | 3342 | 0.320 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2024 | 499 | 0.310 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2017 | 103 | 0.310 |
Why?
|
| Risk | 4 | 2019 | 919 | 0.310 |
Why?
|
| Substance Abuse Detection | 2 | 2025 | 110 | 0.310 |
Why?
|
| Erythrocyte Indices | 1 | 2009 | 33 | 0.310 |
Why?
|
| Adaptation, Psychological | 7 | 2023 | 716 | 0.310 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2020 | 302 | 0.300 |
Why?
|
| Cardiologists | 3 | 2018 | 45 | 0.300 |
Why?
|
| Drug Monitoring | 3 | 2026 | 401 | 0.290 |
Why?
|
| Poverty | 1 | 2013 | 526 | 0.290 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 1044 | 0.290 |
Why?
|
| Weights and Measures | 1 | 2008 | 7 | 0.280 |
Why?
|
| Liver Function Tests | 1 | 2009 | 105 | 0.280 |
Why?
|
| Pain | 2 | 2018 | 789 | 0.280 |
Why?
|
| Prealbumin | 2 | 2025 | 37 | 0.280 |
Why?
|
| Evidence-Based Medicine | 5 | 2025 | 740 | 0.280 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 303 | 0.270 |
Why?
|
| Anemia | 1 | 2009 | 191 | 0.270 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2021 | 668 | 0.270 |
Why?
|
| Consensus | 5 | 2022 | 477 | 0.270 |
Why?
|
| Administration, Oral | 9 | 2021 | 866 | 0.270 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 194 | 0.260 |
Why?
|
| Research Design | 5 | 2023 | 1137 | 0.260 |
Why?
|
| Multivariate Analysis | 7 | 2013 | 1547 | 0.260 |
Why?
|
| Patient Satisfaction | 5 | 2024 | 709 | 0.260 |
Why?
|
| Internationality | 1 | 2008 | 156 | 0.260 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 329 | 0.260 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2008 | 68 | 0.260 |
Why?
|
| Mitral Valve | 1 | 2008 | 95 | 0.260 |
Why?
|
| Betacoronavirus | 2 | 2020 | 288 | 0.250 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2022 | 63 | 0.250 |
Why?
|
| Pilot Projects | 7 | 2026 | 1891 | 0.250 |
Why?
|
| Models, Cardiovascular | 1 | 2008 | 196 | 0.250 |
Why?
|
| Reminder Systems | 2 | 2025 | 140 | 0.250 |
Why?
|
| Incidence | 10 | 2018 | 2923 | 0.250 |
Why?
|
| Congresses as Topic | 4 | 2025 | 223 | 0.250 |
Why?
|
| Hospitals, Community | 2 | 2020 | 67 | 0.240 |
Why?
|
| Troponin | 2 | 2024 | 50 | 0.240 |
Why?
|
| Erythrocytes | 2 | 2009 | 748 | 0.240 |
Why?
|
| Counselors | 1 | 2026 | 10 | 0.240 |
Why?
|
| Choice Behavior | 2 | 2020 | 180 | 0.240 |
Why?
|
| Prosthesis Design | 4 | 2018 | 354 | 0.230 |
Why?
|
| Patient Care | 2 | 2023 | 119 | 0.230 |
Why?
|
| Sodium | 2 | 2024 | 198 | 0.230 |
Why?
|
| Genetic Counseling | 1 | 2026 | 80 | 0.230 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 875 | 0.230 |
Why?
|
| Prosthesis Implantation | 2 | 2019 | 154 | 0.230 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 467 | 0.230 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 2382 | 0.230 |
Why?
|
| Fatigue | 4 | 2018 | 364 | 0.230 |
Why?
|
| Referral and Consultation | 5 | 2023 | 867 | 0.220 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2025 | 15 | 0.220 |
Why?
|
| Marijuana Smoking | 2 | 2020 | 249 | 0.220 |
Why?
|
| Frailty | 2 | 2019 | 205 | 0.220 |
Why?
|
| Patient Compliance | 4 | 2019 | 587 | 0.220 |
Why?
|
| Neoplasms | 4 | 2023 | 2906 | 0.210 |
Why?
|
| Electric Countershock | 3 | 2020 | 126 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 969 | 0.210 |
Why?
|
| Prevalence | 9 | 2020 | 2865 | 0.210 |
Why?
|
| Digital Divide | 1 | 2024 | 3 | 0.210 |
Why?
|
| Mortality | 4 | 2020 | 378 | 0.210 |
Why?
|
| Health Services Needs and Demand | 1 | 2025 | 280 | 0.200 |
Why?
|
| Mass Screening | 2 | 2010 | 1360 | 0.200 |
Why?
|
| Exercise | 2 | 2026 | 2198 | 0.200 |
Why?
|
| Checklist | 1 | 2024 | 110 | 0.200 |
Why?
|
| Creatinine | 3 | 2023 | 515 | 0.200 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 428 | 0.200 |
Why?
|
| Probability | 3 | 2016 | 307 | 0.200 |
Why?
|
| Mobile Applications | 2 | 2024 | 199 | 0.200 |
Why?
|
| Clinical Coding | 2 | 2014 | 29 | 0.200 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 3 | 0.190 |
Why?
|
| Primary Prevention | 1 | 2025 | 219 | 0.190 |
Why?
|
| Hydralazine | 1 | 2023 | 6 | 0.190 |
Why?
|
| Genetic Testing | 1 | 2026 | 480 | 0.190 |
Why?
|
| Sports Medicine | 1 | 2025 | 118 | 0.190 |
Why?
|
| Urea | 1 | 2023 | 85 | 0.190 |
Why?
|
| Drug Utilization | 2 | 2015 | 168 | 0.190 |
Why?
|
| Denmark | 1 | 2023 | 51 | 0.190 |
Why?
|
| Cardiac Rehabilitation | 1 | 2023 | 46 | 0.190 |
Why?
|
| Perinatal Care | 1 | 2023 | 59 | 0.190 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 3413 | 0.190 |
Why?
|
| Self-Management | 1 | 2025 | 202 | 0.190 |
Why?
|
| Cognition | 5 | 2024 | 1266 | 0.190 |
Why?
|
| Medical Marijuana | 2 | 2024 | 122 | 0.190 |
Why?
|
| Depression | 4 | 2020 | 1546 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 412 | 0.180 |
Why?
|
| Death | 1 | 2023 | 132 | 0.180 |
Why?
|
| Sports | 1 | 2025 | 211 | 0.180 |
Why?
|
| Pulmonary Artery | 1 | 2008 | 1127 | 0.180 |
Why?
|
| Recovery of Function | 4 | 2020 | 716 | 0.180 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 1102 | 0.180 |
Why?
|
| Atrial Appendage | 1 | 2022 | 36 | 0.180 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 29 | 0.170 |
Why?
|
| Glucose | 2 | 2024 | 1048 | 0.170 |
Why?
|
| Pandemics | 2 | 2020 | 1707 | 0.170 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2021 | 82 | 0.170 |
Why?
|
| Advisory Committees | 2 | 2021 | 229 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 1101 | 0.170 |
Why?
|
| Universities | 1 | 2023 | 445 | 0.170 |
Why?
|
| Athletes | 1 | 2025 | 424 | 0.170 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 98 | 0.170 |
Why?
|
| Myocardial Contraction | 2 | 2019 | 293 | 0.160 |
Why?
|
| Age Distribution | 3 | 2012 | 403 | 0.160 |
Why?
|
| Relaxin | 1 | 2020 | 18 | 0.160 |
Why?
|
| Norway | 1 | 2020 | 41 | 0.160 |
Why?
|
| Georgia | 1 | 2020 | 79 | 0.160 |
Why?
|
| Hypertension | 3 | 2021 | 1273 | 0.160 |
Why?
|
| Trust | 1 | 2022 | 155 | 0.160 |
Why?
|
| Health Systems Plans | 1 | 2020 | 3 | 0.160 |
Why?
|
| Health Services Misuse | 1 | 2020 | 35 | 0.160 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 308 | 0.160 |
Why?
|
| Psychology | 1 | 2021 | 86 | 0.160 |
Why?
|
| Anxiety | 3 | 2018 | 1118 | 0.160 |
Why?
|
| Financing, Government | 1 | 2020 | 53 | 0.160 |
Why?
|
| Palliative Medicine | 2 | 2018 | 24 | 0.160 |
Why?
|
| Health Resources | 2 | 2012 | 130 | 0.150 |
Why?
|
| Diagnosis-Related Groups | 2 | 2021 | 35 | 0.150 |
Why?
|
| Self Report | 1 | 2024 | 870 | 0.150 |
Why?
|
| Thoracentesis | 1 | 2019 | 6 | 0.150 |
Why?
|
| Odds Ratio | 5 | 2014 | 1082 | 0.150 |
Why?
|
| Home Care Services | 2 | 2020 | 284 | 0.150 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 147 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 170 | 0.150 |
Why?
|
| Mandatory Programs | 1 | 2019 | 16 | 0.150 |
Why?
|
| Nurses | 3 | 2018 | 171 | 0.150 |
Why?
|
| Pyridones | 1 | 2021 | 209 | 0.150 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2019 | 31 | 0.150 |
Why?
|
| Mental Competency | 1 | 2019 | 26 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 195 | 0.150 |
Why?
|
| Dyspnea | 3 | 2018 | 250 | 0.140 |
Why?
|
| Home Infusion Therapy | 1 | 2018 | 4 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2022 | 409 | 0.140 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 266 | 0.140 |
Why?
|
| Fee-for-Service Plans | 2 | 2018 | 99 | 0.140 |
Why?
|
| Contraindications | 2 | 2015 | 90 | 0.140 |
Why?
|
| Ventricular Function | 1 | 2018 | 53 | 0.140 |
Why?
|
| Coronary Artery Disease | 3 | 2019 | 749 | 0.140 |
Why?
|
| Cooperative Behavior | 2 | 2024 | 462 | 0.140 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 79 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 782 | 0.130 |
Why?
|
| Thromboembolism | 2 | 2021 | 129 | 0.130 |
Why?
|
| Cost Savings | 2 | 2021 | 86 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2018 | 96 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 2028 | 0.130 |
Why?
|
| Patient Safety | 3 | 2021 | 356 | 0.130 |
Why?
|
| Quality Control | 1 | 2017 | 161 | 0.130 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 390 | 0.130 |
Why?
|
| Medical Records | 1 | 2018 | 192 | 0.130 |
Why?
|
| Machine Learning | 1 | 2023 | 587 | 0.130 |
Why?
|
| Spiritual Therapies | 1 | 2017 | 13 | 0.130 |
Why?
|
| Vaccines | 1 | 2022 | 388 | 0.130 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 1193 | 0.120 |
Why?
|
| Caliciviridae Infections | 1 | 2016 | 18 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 3 | 2026 | 765 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 400 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 286 | 0.120 |
Why?
|
| Blood Coagulation | 1 | 2018 | 274 | 0.120 |
Why?
|
| Mexiletine | 1 | 2016 | 6 | 0.120 |
Why?
|
| Amphetamine | 1 | 2016 | 38 | 0.120 |
Why?
|
| Defibrillators | 1 | 2016 | 23 | 0.120 |
Why?
|
| Mental Health | 1 | 2023 | 793 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 164 | 0.120 |
Why?
|
| Truth Disclosure | 1 | 2016 | 51 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 2121 | 0.110 |
Why?
|
| Social Security | 1 | 2015 | 5 | 0.110 |
Why?
|
| Medical Indigency | 1 | 2015 | 11 | 0.110 |
Why?
|
| Pain Management | 2 | 2016 | 410 | 0.110 |
Why?
|
| Uncertainty | 1 | 2016 | 146 | 0.110 |
Why?
|
| Psychotherapy | 1 | 2017 | 181 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2012 | 1490 | 0.110 |
Why?
|
| Bereavement | 1 | 2016 | 71 | 0.110 |
Why?
|
| Young Adult | 9 | 2019 | 14218 | 0.110 |
Why?
|
| Public Health | 1 | 2020 | 572 | 0.110 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 519 | 0.110 |
Why?
|
| Transplant Recipients | 1 | 2016 | 181 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2017 | 266 | 0.110 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 40 | 0.110 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2014 | 27 | 0.110 |
Why?
|
| Assisted Circulation | 1 | 2014 | 26 | 0.110 |
Why?
|
| Polypharmacy | 1 | 2015 | 94 | 0.100 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 130 | 0.100 |
Why?
|
| Social Support | 4 | 2025 | 646 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 2381 | 0.100 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 90 | 0.100 |
Why?
|
| Health Surveys | 3 | 2023 | 518 | 0.100 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 90 | 0.100 |
Why?
|
| Echocardiography | 2 | 2014 | 647 | 0.100 |
Why?
|
| Kidney | 2 | 2020 | 1497 | 0.100 |
Why?
|
| Cobalt | 1 | 2014 | 50 | 0.100 |
Why?
|
| Potassium | 1 | 2013 | 152 | 0.100 |
Why?
|
| Infant, Low Birth Weight | 1 | 2014 | 156 | 0.100 |
Why?
|
| Data Collection | 1 | 2016 | 640 | 0.100 |
Why?
|
| Calcium | 1 | 2019 | 1190 | 0.090 |
Why?
|
| Digestive System Diseases | 1 | 2013 | 28 | 0.090 |
Why?
|
| Women's Health | 1 | 2015 | 314 | 0.090 |
Why?
|
| Anthracyclines | 1 | 2012 | 49 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 507 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2012 | 105 | 0.090 |
Why?
|
| Drug Utilization Review | 1 | 2012 | 61 | 0.090 |
Why?
|
| Critical Care | 1 | 2018 | 702 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2214 | 0.090 |
Why?
|
| Patients | 2 | 2024 | 183 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 239 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 62 | 0.090 |
Why?
|
| Acculturation | 1 | 2012 | 55 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 288 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2023 | 6447 | 0.090 |
Why?
|
| Running | 1 | 2014 | 233 | 0.080 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2012 | 71 | 0.080 |
Why?
|
| Tachycardia | 1 | 2011 | 57 | 0.080 |
Why?
|
| Culture | 1 | 2012 | 124 | 0.080 |
Why?
|
| Hyponatremia | 1 | 2011 | 43 | 0.080 |
Why?
|
| Birth Weight | 1 | 2014 | 514 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 1097 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 285 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2015 | 541 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2017 | 780 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2019 | 2445 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 919 | 0.080 |
Why?
|
| Motivation | 1 | 2015 | 600 | 0.080 |
Why?
|
| Health Services Research | 1 | 2013 | 391 | 0.080 |
Why?
|
| Logistic Models | 2 | 2013 | 2134 | 0.080 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2010 | 10 | 0.080 |
Why?
|
| Pregnancy | 1 | 2023 | 7202 | 0.080 |
Why?
|
| Heart | 1 | 2014 | 626 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2020 | 330 | 0.080 |
Why?
|
| Benzazepines | 1 | 2010 | 35 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 197 | 0.080 |
Why?
|
| Erythropoiesis | 1 | 2009 | 57 | 0.080 |
Why?
|
| Minority Groups | 1 | 2012 | 284 | 0.080 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 62 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1508 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 443 | 0.070 |
Why?
|
| Endpoint Determination | 1 | 2009 | 85 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 85 | 0.070 |
Why?
|
| Bilirubin | 1 | 2009 | 99 | 0.070 |
Why?
|
| Actuarial Analysis | 1 | 2008 | 16 | 0.070 |
Why?
|
| Focus Groups | 2 | 2023 | 569 | 0.070 |
Why?
|
| Alberta | 1 | 2008 | 25 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 368 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 151 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 144 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 208 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 381 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 617 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 147 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2011 | 375 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 1435 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2664 | 0.060 |
Why?
|
| Insurance Coverage | 2 | 2021 | 244 | 0.060 |
Why?
|
| Ultrafiltration | 1 | 2007 | 28 | 0.060 |
Why?
|
| Heart Function Tests | 1 | 2007 | 59 | 0.060 |
Why?
|
| Social Workers | 2 | 2018 | 55 | 0.060 |
Why?
|
| Exercise Test | 2 | 2023 | 630 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 992 | 0.060 |
Why?
|
| Child | 2 | 2023 | 22707 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2007 | 189 | 0.060 |
Why?
|
| Taiwan | 1 | 2025 | 48 | 0.060 |
Why?
|
| Precision Medicine | 2 | 2024 | 459 | 0.060 |
Why?
|
| Nebraska | 1 | 2025 | 21 | 0.060 |
Why?
|
| Wyoming | 1 | 2025 | 27 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2009 | 305 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2018 | 500 | 0.060 |
Why?
|
| Delayed Diagnosis | 1 | 2025 | 100 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 330 | 0.050 |
Why?
|
| Genomics | 1 | 2010 | 825 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2025 | 52 | 0.050 |
Why?
|
| Lung | 1 | 2018 | 4106 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2006 | 224 | 0.050 |
Why?
|
| Troponin T | 1 | 2024 | 63 | 0.050 |
Why?
|
| Natriuretic Peptides | 1 | 2023 | 9 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2025 | 168 | 0.050 |
Why?
|
| Troponin I | 1 | 2024 | 73 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2020 | 1111 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1266 | 0.050 |
Why?
|
| Group Processes | 1 | 2024 | 63 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2013 | 1163 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 133 | 0.050 |
Why?
|
| Proteomics | 1 | 2010 | 1188 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 74 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 80 | 0.050 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2023 | 18 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2023 | 179 | 0.050 |
Why?
|
| Heuristics | 1 | 2022 | 11 | 0.050 |
Why?
|
| Information Systems | 1 | 2023 | 56 | 0.050 |
Why?
|
| Cannabinoids | 1 | 2025 | 184 | 0.050 |
Why?
|
| Empiricism | 1 | 2022 | 2 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 17 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 2378 | 0.050 |
Why?
|
| Sexism | 1 | 2023 | 68 | 0.040 |
Why?
|
| Critical Illness | 1 | 2008 | 900 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2022 | 64 | 0.040 |
Why?
|
| Massachusetts | 1 | 2022 | 180 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 610 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2024 | 275 | 0.040 |
Why?
|
| Program Development | 1 | 2023 | 368 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 3155 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 148 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3904 | 0.040 |
Why?
|
| Return to Sport | 1 | 2022 | 117 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2022 | 109 | 0.040 |
Why?
|
| Urban Health Services | 1 | 2020 | 69 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 345 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 259 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 17 | 0.040 |
Why?
|
| Private Sector | 1 | 2020 | 50 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 150 | 0.040 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 34 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 62 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 84 | 0.040 |
Why?
|
| Embolism | 1 | 2019 | 48 | 0.040 |
Why?
|
| Contraindications, Procedure | 1 | 2019 | 13 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 34 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 344 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2023 | 530 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2020 | 138 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 431 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2019 | 85 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 104 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 120 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 133 | 0.040 |
Why?
|
| Government Regulation | 1 | 2018 | 39 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 123 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 134 | 0.030 |
Why?
|
| Survival | 1 | 2018 | 38 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 360 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 381 | 0.030 |
Why?
|
| Policy Making | 1 | 2018 | 83 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2022 | 693 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 27 | 0.030 |
Why?
|
| Medicare Part D | 1 | 2018 | 23 | 0.030 |
Why?
|
| Walk Test | 1 | 2018 | 81 | 0.030 |
Why?
|
| Patient Health Questionnaire | 1 | 2018 | 40 | 0.030 |
Why?
|
| Hospitals, Rural | 1 | 2018 | 49 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1997 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2023 | 782 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 142 | 0.030 |
Why?
|
| Risk Management | 1 | 2018 | 82 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 365 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 217 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1368 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 318 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 283 | 0.030 |
Why?
|
| Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2025 | 1196 | 0.030 |
Why?
|
| Antidiarrheals | 1 | 2016 | 12 | 0.030 |
Why?
|
| Loperamide | 1 | 2016 | 12 | 0.030 |
Why?
|
| Atropine | 1 | 2016 | 37 | 0.030 |
Why?
|
| Emotional Adjustment | 1 | 2016 | 18 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 37 | 0.030 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 7 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2016 | 30 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2953 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 978 | 0.030 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2016 | 9 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 65 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 351 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 132 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 377 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 208 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2016 | 65 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 136 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 866 | 0.030 |
Why?
|
| Life Change Events | 1 | 2016 | 146 | 0.030 |
Why?
|
| Video Recording | 1 | 2016 | 217 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2014 | 32 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2025 | 1735 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 798 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 845 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2015 | 98 | 0.030 |
Why?
|
| Family Relations | 1 | 2015 | 87 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 185 | 0.030 |
Why?
|
| Diastole | 1 | 2014 | 146 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 1041 | 0.020 |
Why?
|
| Morbidity | 1 | 2014 | 322 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 407 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2014 | 258 | 0.020 |
Why?
|
| History, Ancient | 1 | 2013 | 53 | 0.020 |
Why?
|
| Proteinuria | 1 | 2013 | 104 | 0.020 |
Why?
|
| Systole | 1 | 2013 | 181 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 583 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 527 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2012 | 118 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 838 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2018 | 924 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 140 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 390 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2012 | 222 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 423 | 0.020 |
Why?
|
| Medical Audit | 1 | 2011 | 77 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 231 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2012 | 328 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2011 | 140 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 1399 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 264 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 402 | 0.020 |
Why?
|
| Students | 1 | 2014 | 651 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 1957 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2008 | 56 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 71 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 3623 | 0.010 |
Why?
|
| Adolescent | 2 | 2017 | 22529 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2769 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 4075 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1963 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 38030 | 0.000 |
Why?
|